“We are honored to name OnSight as this year’s TCT Shark Tank Innovation Competition winner for their AI-based software for cardiac ultrasound guidance, detection, and analysis,” said Juan F. Granada, MD, President and Chief Executive Officer of the Cardiovascular Research Foundation, the sponsor of TCT. “OnSight has great potential to enhance and expand access to cardiac ultrasound to underserved populations all over the world.”
Cardiac ultrasound, a non-invasive imaging modality used to look at the structure and function of the heart, is typically used to help investigate symptoms and assess heart conditions. The test is usually performed by a specially trained technologist, called a sonographer, and interpreted by a cardiologist trained in reading heart ultrasounds. Using proprietary AI technology, OnSight Medical’s software provides real-time, expert level scans with high-quality 4D images, allowing for patients to get these scans in places with limited access to hospitals or specialists such as rural areas, underserved regions, and underdeveloped countries.
Now in its seventh year, the TCT Shark Tank Innovation Competition was created to highlight the most innovative device concepts and technological developments with the potential to disrupt the cardiovascular field and dramatically change how patients are treated. Six companies were chosen to present their technologies among a distinguished panel of multidisciplinary experts and judged on the following criteria: unmet clinical need, technology differentiation, IP position/viability, biological proof of concept, regulatory pathway, and commercialization potential.
For the third year in a row, the TCT Shark Tank Innovation Competition partnered with the Jon DeHaan Foundation to provide a $200,000 award that will be given to the winner. The Jon DeHaan Foundation is dedicated to supporting those working to advance cardiac medicine and provides grants and awards to individuals and companies who focus on innovative developments in cardiovascular medicine, including research, prevention, diagnosis, treatment or rehabilitation.
“CRF is truly grateful to the Jon DeHaan Foundation for their continued support of pioneers in the field dedicated to developing new treatments for heart and vascular disease,” added Dr. Granada.
“The DeHaan Foundation remains committed to its primary mission of supporting cardiovascular disease innovation,” said Robert Schwartz, MD, President of the Jon DeHaan Foundation. “The partnership with the Cardiovascular Research Foundation and TCT is an ideal collaboration to further this goal. We are pleased to continue these efforts with the Shark Tank sessions at TCT Connect.”
The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 32nd year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.